Lymphoma Research Foundation Elects New Board of Director Leadership
Harriet Greenberg and Joel Pollick Joins Lymphoma Research Foundation Board of Directors
News
2021 Lymphoma Research Foundation Annual Gala and North American Educational Forum on Lymphoma To be Held Virtually
The Lymphoma Research Foundation (LRF) announced today that its premier fundraising event, the LRF Annual Gala, and patient education program, the North American Educational Forum on Lymphoma, will be held virtually in response to the continuing COVID-19 pandemic. The LRF…
Meet the 2021 Career Development Award and Postdoctoral Fellowship Grantees
The LRF Clinical Investigator Career Development Award (CDA) and Postdoctoral Fellowship Grant Program support junior faculty members and PhD and advanced clinical fellows pursuing research in lymphoma and chronic lymphocytic leukemia (CLL).
Paving the Way for Innovation
Dr. Christopher Flowers is passionate about working as a team and sharing with others the same enthusiasm for medicine that he has had since the onset of his career.
An Enduring Legacy of Hope and Impact
Chike Springer was many things — a husband, son, brother, uncle and patriot — but he was most known for his positivity and determination.
U.S. Food and Drug Administration Approves Loncastuximab Tesirine-lpyl for Large B-cell Lymphoma
Loncastuximab tesirine-lpyl is the first and only CD-19-directed antibody drug conjugate single agent approved for relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Ask the Doctor: How can we determine the efficacy of the COVID-19 vaccine and how we may respond?
As the rollout of the new COVID-19 vaccines continues, there is constant new data related to the vaccines and their effects on individuals. While most of this data is preliminary, information related to the efficacy and effect of the vaccine…
Ask the Doctor: How do physicians determine when follicular lymphoma has transformed to DLBCL? What kind of tests or symptoms help doctors monitor this?
Transformed lymphoma occurs when an indolent lymphoma turns into a more aggressive one. A transformation occurs when genetic changes in the indolent lymphoma cells cause them to begin growing faster and behaving more aggressively. Lymphoma Research Foundation Grantee Raphael Eric…
LRF Honors Michael E. Williams, MD with Mantle Cell Lymphoma Leadership Award
World-renowned hematologist/oncologist receives inaugural award for outstanding commitment in the field of mantle cell lymphoma research and patient care.
Ask the Doctor: What is the current efficacy of oral therapies for marginal zone lymphoma?
There are several chemotherapy and targeted anticancer drugs approved or under investigation for the treatment of lymphoma. Unlike traditional chemotherapy that is administered intravenously (IV) in a hospital or clinic, oral therapies are administered via a pill, taken at home…